Evidence
Diseases. 2024 Mar 29;12(4):69. doi: 10.3390/diseases12040069.
ABSTRACT
Alcoholic liver disease (ALD) is a major cause of chronic liver disease. This term covers a broad spectrum of liver lesions, from simple steatosis to alcoholic hepatitis and cirrhosis. The pathogenesis of ALD is multifactorial and not fully elucidated due to complex mechanisms related to direct ethanol toxicity with subsequent hepatic and systemic inflammation. The accumulation of pro-inflammatory cytokines and the reduction of anti-inflammatory cytokines promote the development and progression of ALD. To date, there are no targeted therapies to counter the progression of chronic alcohol-related liver disease and prevent acute liver failure. Corticosteroids reduce mortality by acting on the hepatic-systemic inflammation. On the other hand, several studies analyzed the effect of inhibiting pro-inflammatory cytokines and stimulating anti-inflammatory cytokines as potential therapeutic targets in ALD. This narrative review aims to clarify the role of the main cytokines involved in the pathogenesis and treatment of ALD.
PMID:38667527 | DOI:10.3390/diseases12040069
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
🌐 90 Days
VR Related Evidence Matrix
- Inflammation in alcohol-associated hepatitis: pathogenesis and therapeutic targets
- Inflammatory liver diseases and susceptibility to sepsis
- Identifying competing endogenous RNA regulatory networks and hub genes in alcoholic liver disease for early diagnosis and potential therapeutic target insights
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Bruceine A alleviates alcoholic liver disease by inhibiting AIM2 inflammasome activation via activating FXR
- Kupffer cell diversity maintains liver function in alcohol-associated liver disease
- Interleukins in liver disease treatment
- A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- NcRNA Regulated Pyroptosis in Liver Diseases and Traditional Chinese Medicine Intervention: A Narrative Review
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Protective Effects of Lycium ruthenicum Murray against Acute Alcoholic Liver Disease in Mice via the Nrf2/HO-1/NF-kappaB Signaling Pathway
- The gut-liver axis in fatty liver disease: role played by natural products
- Metallofullerenol alleviates alcoholic liver damage via ROS clearance under static magnetic and electric fields
- ERRgamma-inducible FGF23 promotes alcoholic liver injury through enhancing CYP2E1 mediated hepatic oxidative stress
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- COVID-19 in Individuals with Chronic Liver Diseases
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Cyanidin-3-O-glucoside alleviates ethanol-induced liver injury by promoting mitophagy in a Gao-binge mouse model of alcohol-associated liver disease
- Fucoidan from Apostichopus japonicus ameliorates alcoholic liver disease by regulating gut-liver axis homeostasis
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Bacteroides and NAFLD: pathophysiology and therapy
- Inflammatory Protein Signatures as Predictive Disease-Specific Markers for Non-Alcoholic Steatohepatitis (NASH)
- Liver cirrhosis in a patient with alcohol dependence and autoimmune hepatitis
- Spatial genomics: mapping human steatotic liver disease
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases)
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- The double roles of T cell-mediated immune response in the progression of MASLD
- Interaction between fatty acid oxidation and ethanol metabolism in liver
- Network medicine-based analysis of the hepatoprotective effects of Amomum villosum Lour. on alcoholic liver disease in rats
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Poria cocos polysaccharides improve alcoholic liver disease by interfering with ferroptosis through NRF2 regulation
- Deletion of Mixed Lineage Kinase Domain Like Pseudokinase Aggravates Chronic Alcohol-Induced Liver Injury via Increasing Apoptosis
- Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma
- Glucosamine attenuates alcohol-induced acute liver injury via inhibiting oxidative stress and inflammation
- Role of lactate and lactate metabolism in liver diseases (Review)
- Bacillus coagulans regulates gut microbiota and ameliorates the alcoholic-associated liver disease in mice
- Review article: Current indications and selection criteria for early liver transplantation in severe alcohol-associated hepatitis
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Cyanidin-3-O-Glucoside Alleviates Alcoholic Liver Injury via Modulating Gut Microbiota and Metabolites in Mice
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- A PROTEIN COMPLEX OF LIVER ORIGIN ACTIVATES A PRO-INFLAMMATORY PROGRAM THAT DRIVES HEPATIC AND INTESTINAL INJURY IN ALCOHOL-ASSOCIATED LIVER DISEASE
- A PROTEIN COMPLEX OF LIVER ORIGIN ACTIVATES A PRO-INFLAMMATORY PROGRAM THAT DRIVES HEPATIC AND INTESTINAL INJURY IN ALCOHOL-ASSOCIATED LIVER DISEASE
- The Role of Oxidative Stress in Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies
- Alcohol use disorders and liver fibrosis: an update
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Mimicking chronic alcohol effects through a controlled and sustained ethanol release device
- Alcohol-Related liver disease: A global perspective
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review)
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review
- Yanggan Jiangmei Formula alleviates hepatic inflammation and lipid accumulation in non-alcoholic steatohepatitis by inhibiting the NF-kappaB/NLRP3 signaling pathway
- Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
- Mechanism of Shenling Baizhu Powder on treatment of alcoholic liver disease by regulating TLR4/NLRP3 pathway
- Lactiplantibacillus plantarum ZDY2013 Inhibits the Development of Non-Alcoholic Fatty Liver Disease by Regulating the Intestinal Microbiota and Modulating the PI3K/Akt Pathway
Evidence Blueprint
The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease
🌐 365 Days
VR Related Evidence Matrix
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- Ambiguous Pathogenic Roles of Macrophages in Alcohol-Associated Liver Diseases
- Human Precision-Cut Liver Slices: A Potential Platform to Study Alcohol-Related Liver Disease
- Molecular insights on intracellular Wnt/β-catenin signaling in alcoholic liver disease
- Molecular insights on intracellular Wnt/β-catenin signaling in alcoholic liver disease
- Alcohol and the mechanisms of liver disease
- Inflammation in alcohol-associated hepatitis: pathogenesis and therapeutic targets
- Glabridin Ameliorates Alcohol-Caused Liver Damage by Reducing Oxidative Stress and Inflammation via p38 MAPK/Nrf2/NF-κB Pathway
- Inflammatory liver diseases and susceptibility to sepsis
- Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases
- Identifying competing endogenous RNA regulatory networks and hub genes in alcoholic liver disease for early diagnosis and potential therapeutic target insights
- Endoplasmic reticulum stress in the pathogenesis of alcoholic liver disease
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Bruceine A alleviates alcoholic liver disease by inhibiting AIM2 inflammasome activation via activating FXR
- Kupffer cell diversity maintains liver function in alcohol-associated liver disease
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Interleukins in liver disease treatment
- NLRP3: a new therapeutic target in alcoholic liver disease
- Progress in the mechanism of autophagy and traditional Chinese medicine herb involved in alcohol-related liver disease
- Therapeutic potential of oleanolic acid in liver diseases
- Management of alcoholic hepatitis: A clinical perspective
- Insights of mitochondrial involvement in alcoholic fatty liver disease
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease
- Role of prostaglandin E2 and its receptors in chronic liver disease
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- 1H NMR Serum Metabolomic Change of Trimethylamine N-oxide (TMAO) Is Associated with Alcoholic Liver Disease Progression
- Current and future treatment for alcoholic-related liver diseases
- Integrated Multidisciplinary Management of Alcohol-associated Liver Disease
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- ZONAL EXPRESSION OF STARD1 AND OXIDATIVE STRESS IN ALCOHOLIC-RELATED LIVER DISEASE
- NcRNA Regulated Pyroptosis in Liver Diseases and Traditional Chinese Medicine Intervention: A Narrative Review
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Protective Effects of Lycium ruthenicum Murray against Acute Alcoholic Liver Disease in Mice via the Nrf2/HO-1/NF-kappaB Signaling Pathway
- The gut-liver axis in fatty liver disease: role played by natural products
- Metallofullerenol alleviates alcoholic liver damage via ROS clearance under static magnetic and electric fields
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Protection of Inonotus hispidus (Bull.) P. Karst. against Chronic Alcohol-Induced Liver Injury in Mice via Its Relieving Inflammation Response
- ERRgamma-inducible FGF23 promotes alcoholic liver injury through enhancing CYP2E1 mediated hepatic oxidative stress
- Corrected and republished from: Metabolic associated liver disease
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Aldo-keto reductase family 1 member A1 (AKR1A1) exerts a protective function in alcohol-associated liver disease by reducing 4-HNE accumulation and p53 activation
- Mitochondrial dysfunction: A promising therapeutic target for liver diseases
- The Monoacylglycerol Lipase Inhibitor ABX-1431 Does Not Improve Alcoholic Liver Disease
- Porphyromonas gingivalis exacerbates alcoholic liver disease by altering gut microbiota composition and host immune response in mice
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- The role of neutrophils in alcohol-related hepatitis
- Occult liver disease: a multinational perspective
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- COVID-19 in Individuals with Chronic Liver Diseases
- Drinking and laboratory biomarkers, and nutritional status characterize the clinical presentation of early-stage alcohol-associated liver disease
- Time-Restricted Feeding Ameliorates Methionine-Choline Deficient Diet-Induced Steatohepatitis in Mice
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Recent insight into the role of macrophage in alcohol-associated liver disease: a mini-review
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- Multiple Dimensions of using Mesenchymal Stem Cells for Treating Liver Diseases: From Bench to Beside
- Dissecting the potential role of ferroptosis in liver diseases: an updated review